Vanguard Global Advisers
ATOS icon

Vanguard Global Advisers’s Atossa Therapeutics ATOS Stock Holding History

Vanguard Global Advisers’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96K Hold
3,089
– – ﹤0.01% 3536
2026
Q1 		$16.2K Buy
+3,089
New +$19.6K ﹤0.01% 3374

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Global Advisers's ATOS Position: Q2 2026 in Review

Vanguard Global Advisers held its Atossa Therapeutics (ATOS) position steady in Q2 2026 at 3,089 shares worth $5.96K. The position accounts for ﹤0.01% of the portfolio, ranked #3536.

Vanguard Global Advisers first reported a position in ATOS in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.2K in Q1 2026. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Vanguard Global Advisers held 3,089 shares of Atossa Therapeutics worth $5.96K as of Q2 2026.
  • Vanguard Global Advisers left its Atossa Therapeutics share count unchanged in Q2 2026.
  • Atossa Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3536 holding.
  • Vanguard Global Advisers first reported a position in Atossa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Atossa Therapeutics position peaked at $16.2K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.